![](jpg/gettyimages-1280895783-150x150.jpg)
Click Therapeutics
-
Devices & Diagnostics, BioPharma
Click Expands to Substance Use Disorder With Indivior Digital Therapeutics Pact
Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Click’s third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.
-
Click Therapeutics raises $52M, looks to advance digital therapeutics
Click Therapeutics is developing digital therapeutics for depression, insomnia and other conditions. It plans to use the funds to commercialize its therapeutics, through partnerships with pharmaceutical companies including Otsuka.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Otsuka launches pivotal trial of digital therapeutics for depression
Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms.
-
Startups, Events, BioPharma, Pharma
Here’s Otsuka’s digital health strategy around mental health
Otsuka’s top U.S.-based leaders spoke about the company’s partnerships in mental health and how it is driving innovation in big pharma.
-
Rock Health: Digital health investing has already surpassed record-breaking 2017
In 2018 alone, ten companies have inked mega-deals of more than $100 million including Livongo, 23andMe and American Well.